100 patient multi-center study of the Episealer® knee implant fully recruited
Episurf Medical (NASDAQ: EPIS B) today announces that a European large multi-center study with 100 Episealer patients has been fully recruited. The patients are followed-up at 3, 6, 12, 24 and 60 months post-operatively with clinical scores focusing on pain relief and knee function. The patients have been enrolled since 2014 and the last surgery was recently performed. The surgeons involved in the clinical study are eleven leading European orthopaedic surgeons. Dr. Med. Johannes Holz from Orthocentrum Hamburg, Germany, has been appointed principal investigator for the study. The study is